Related Experiment Video

Updated: Jun 14, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

254

Role of PD-1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance

Neha Sharma1, Rupa Mazumder1, Pallavi Rai2

  • 1Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, India.

Chemical Biology & Drug Design
|September 4, 2024
PubMed

Insights

This study examines programmed cell death protein 1 (PD-1) in skin cancer, detailing its role in immune evasion and therapeutic potential. It also addresses resistance mechanisms to PD-1 inhibitors, crucial for improving skin cancer treatment outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Skin cancer, including melanoma, squamous cell carcinoma, and basal cell carcinoma, is a global health issue.
  • Early detection and treatment are vital due to the limited curability of many subtypes.
  • Immune checkpoints, particularly programmed cell death protein 1 (PD-1), play a critical role in tumor immune evasion.

Purpose of the Study:

  • To explore the function of PD-1 in skin cancer pathogenesis and immune regulation.
  • To evaluate the clinical efficacy and challenges of PD-1 inhibitors in treating skin cancer.
  • To investigate resistance mechanisms and propose strategies for enhancing PD-1 inhibitor therapy.

Main Methods:

  • Comprehensive literature review and analysis of existing research on PD-1 and skin cancer.
  • Examination of molecular mechanisms underlying PD-1's role in immune evasion.
  • Critical evaluation of clinical trial data and therapeutic strategies involving PD-1 inhibitors.

Main Results:

  • PD-1 is a key regulator of immune responses in the tumor microenvironment, facilitating immune evasion.
  • PD-1 inhibitors show significant therapeutic potential for various skin cancers.
  • Development of resistance to PD-1 inhibitors is a major clinical challenge, with diverse underlying mechanisms.

Conclusions:

  • Understanding PD-1's role is crucial for advancing skin cancer immunotherapy.
  • Strategies to overcome resistance are essential for maximizing the benefits of PD-1 targeted therapies.
  • Further research is needed to optimize PD-1 inhibitor treatments for improved patient outcomes in skin cancer.
Keywords:
PD‐1 in skin cancerPD‐1 inhibitor resistancebasal cell carcinomacancer immunotherapyimmune checkpoint inhibitorsmelanomamolecular mechanisms of PD‐1squamous cell carcinomatherapeutic strategies in skin cancer

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.1K

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
2.5K